Section 1847A(i)(5) of the Act requires that for Part B rebatable drugs, as defined in section 1847A(i)(2)(A) of the Act, furnished on or after April 1, 2023, in quarters in which the payment amount described in section 1847A(i)(3)(A)(ii)(I) of the Act (or, in the case of selected drugs described under section 1192(c) of the Act, the payment amount described in section 1847A(b)(1)(B) of the Act), exceeds the inflation-adjusted payment amount determined in accordance with section 1847A(i)(3)(C) of the Act, the coinsurance will be 20 percent of the inflation-adjusted payment amount for such quarter (hereafter, the inflation-adjusted coinsurance amount)
NHS access to these medicines is subject to NICE eligibility criteria, which typically include BMI thresholds, the presence of weight-related comorbidities, and involvement of a specialist weight management service
This page is designed to help readers distinguish documented facts from company claims and individual anecdotes before paying
1 Introduction Childhood obesity has risen dramatically worldwide
These doses mirror those used in clinical trials, which means you get proven support for your thyroid while enjoying a more convenient and better-tasting delivery method
